Last updated: March 2026
GLP-1 Receptor Agonist • Weight Loss & Diabetes Management
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1. Originally developed for type 2 diabetes treatment, it has gained significant attention for its powerful weight loss effects. The medication works by slowing gastric emptying, reducing appetite, and improving insulin sensitivity.
Semaglutide represents a breakthrough in both diabetes management and obesity treatment, offering clinically proven results in multiple large-scale trials including STEP (Semaglutide Treatment Effect in People with obesity) studies.
The FDA first approved semaglutide in 2017 for diabetes (Ozempic), followed by weight management approval in 2021 (Wegovy). This regulatory approval distinguishes semaglutide from research peptides, providing established safety and efficacy data.
Semaglutide activates GLP-1 receptors throughout the body, producing multiple beneficial effects:
Semaglutide dosing follows a gradual escalation protocol to minimize gastrointestinal side effects while achieving optimal therapeutic effect.
| Weeks | Dose | Purpose | Notes |
|---|---|---|---|
| 1-4 | 0.25mg weekly | Initial tolerance | Sub-therapeutic, for GI adaptation |
| 5-8 | 0.5mg weekly | Early therapeutic | Some weight loss typically begins |
| 9-12 | 1mg weekly | Therapeutic range | Significant weight loss expected |
| 13-16 | 1.7mg weekly | Higher therapeutic | Optional step before maximum |
| 17+ | 2.4mg weekly | Maximum approved | Highest efficacy for weight loss |
| Phase | Dose | Duration |
|---|---|---|
| Starting | 0.25mg weekly | 4 weeks |
| Maintenance | 0.5mg weekly | Ongoing |
| If needed | 1mg weekly | After 4+ weeks on 0.5mg |
Research-grade semaglutide typically comes as lyophilized powder requiring reconstitution with bacteriostatic water. Common vial sizes and reconstitution ratios:
Calculate your exact injection volume based on vial size, water amount, and target dose.
Comparing the three major GLP-1 receptor agonists for weight loss and metabolic health:
| Aspect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1/GIP dual agonist | GLP-1/GIP/Glucagon triple agonist |
| FDA Status | Approved (Ozempic, Wegovy) | Approved (Mounjaro, Zepbound) | Phase III trials |
| Weight Loss | 15-20% body weight | 20-25% body weight | 25-30% body weight (early data) |
| Dosing | Weekly injection | Weekly injection | Weekly injection |
| Max Dose | 2.4mg (Wegovy) | 15mg (Zepbound) | 12mg (trials) |
| Side Effects | Moderate GI symptoms | Similar to semaglutide | Higher GI symptoms initially |
| Cost (Brand) | $1,300-1,400/month | $1,400-1,500/month | Not yet available |
Semaglutide's most common side effects are gastrointestinal, typically occurring during dose escalation phases and often improving with time.
| Form | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilized powder | 2-8°C (36-46°F) | 2+ years | Protect from light |
| Reconstituted solution | 2-8°C (36-46°F) | 4-6 weeks | Use bacteriostatic water |
| Pre-filled pen (Ozempic/Wegovy) | 2-8°C (36-46°F) | Until expiration | 30 days at room temp after first use |
Storage Tips: Never freeze semaglutide. Keep in original packaging to protect from light. If traveling, use insulated cooling packs but avoid direct contact with ice.
Clinical trial data demonstrates significant weight loss with semaglutide across multiple studies:
| Timeframe | Expected Weight Loss | Notes |
|---|---|---|
| Month 1-2 | 2-5% body weight | Initial response, appetite suppression |
| Month 3-6 | 8-12% body weight | Steady loss phase |
| Month 6-12 | 12-18% body weight | Approaching plateau |
| Month 12+ | Maintenance phase | Focus on weight maintenance |
Appetite suppression typically begins within 1-2 weeks. Significant weight loss usually starts by week 4-8, with peak effects occurring around 6-12 months of treatment.
While there's no dangerous withdrawal syndrome, most people regain weight when stopping semaglutide. Many healthcare providers recommend gradual dose reduction and transition to lifestyle maintenance strategies.
If missed by ≤5 days, take as soon as remembered. If >5 days late, skip the missed dose and resume normal schedule. Don't double dose.
Alcohol isn't contraindicated, but semaglutide can reduce alcohol tolerance and potentially increase nausea. Many users report decreased alcohol cravings.
Coverage varies significantly. Ozempic (diabetes) has better coverage than Wegovy (weight loss). Many insurers require prior authorization and documented weight loss attempts.
Compounded versions may be less expensive but lack FDA oversight for consistency and purity. Quality can vary between compounding pharmacies. Brand name products have guaranteed potency and sterility.
Rapid weight loss can include muscle mass. Combining semaglutide with resistance training and adequate protein intake (0.8-1.2g/kg body weight) helps preserve lean mass during weight loss.
Long-term safety data extends to 2-3 years in clinical trials. The medication appears safe for extended use in most people, though long-term effects beyond 3 years require more study.
Use our tracking tools to monitor weight loss, side effects, and dosing schedule.
Access Calculator →